These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35200182)

  • 1. New Treatment for Polycythemia Vera.
    Aschenbrenner DS
    Am J Nurs; 2022 Mar; 122(3):18-19. PubMed ID: 35200182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera.
    Gerds AT; Castro C; Snopek F; Flynn MM; Ellis AG; Manning M; Urbanski R
    J Comp Eff Res; 2023 Sep; 12(9):e230066. PubMed ID: 37531245
    [No Abstract]   [Full Text] [Related]  

  • 3. Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.
    Wagner SM; Melchardt T; Greil R
    Drugs Today (Barc); 2020 Mar; 56(3):195-202. PubMed ID: 32282866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
    Gisslinger H; Klade C; Georgiev P; Krochmalczyk D; Gercheva-Kyuchukova L; Egyed M; Rossiev V; Dulicek P; Illes A; Pylypenko H; Sivcheva L; Mayer J; Yablokova V; Krejcy K; Grohmann-Izay B; Hasselbalch HC; Kralovics R; Kiladjian JJ;
    Lancet Haematol; 2020 Mar; 7(3):e196-e208. PubMed ID: 32014125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.
    Illés Á; Pinczés LI; Egyed M
    Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):3-7. PubMed ID: 33118413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.
    Edahiro Y; Ohishi K; Gotoh A; Takenaka K; Shibayama H; Shimizu T; Usuki K; Shimoda K; Ito M; VanWart SA; Zagrijtschuk O; Qin A; Kawase H; Miyachi N; Sato T; Komatsu N; Kirito K
    Int J Hematol; 2022 Aug; 116(2):215-227. PubMed ID: 35430707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ropeginterferon alfa-2 b for the therapy of polycythemia vera].
    Červinek L
    Vnitr Lek; 2020; 66(5):309-313. PubMed ID: 32942868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
    Barbui T; Vannucchi AM; De Stefano V; Masciulli A; Carobbio A; Ferrari A; Ghirardi A; Rossi E; Ciceri F; Bonifacio M; Iurlo A; Palandri F; Benevolo G; Pane F; Ricco A; Carli G; Caramella M; Rapezzi D; Musolino C; Siragusa S; Rumi E; Patriarca A; Cascavilla N; Mora B; Cacciola E; Mannarelli C; Loscocco GG; Guglielmelli P; Betti S; Lunghi F; Scaffidi L; Bucelli C; Vianelli N; Bellini M; Finazzi MC; Tognoni G; Rambaldi A
    Lancet Haematol; 2021 Mar; 8(3):e175-e184. PubMed ID: 33476571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis.
    Huang YW; Qin A; Tsai CY; Chen PJ
    Viruses; 2022 May; 14(6):. PubMed ID: 35746606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B.
    Huang YW; Hsu CW; Lu SN; Yu ML; Su CW; Su WW; Chien RN; Hsu CS; Hsu SJ; Lai HC; Qin A; Tseng KC; Chen PJ
    Hepatol Int; 2020 Dec; 14(6):997-1008. PubMed ID: 33099752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment.
    Qin A
    Clin Ther; 2024 May; 46(5):439-440. PubMed ID: 38697872
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.
    Jin J; Qin A; Zhang L; Shen W; Wang W; Zhang J; Li Y; Wu D; Xiao Z
    Future Oncol; 2023 Apr; 19(11):753-761. PubMed ID: 37129584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration.
    Miyachi N; Zagrijtschuk O; Kang L; Yonezu K; Qin A
    Clin Drug Investig; 2021 Apr; 41(4):391-404. PubMed ID: 33725322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.
    Gisslinger H; Zagrijtschuk O; Buxhofer-Ausch V; Thaler J; Schloegl E; Gastl GA; Wolf D; Kralovics R; Gisslinger B; Strecker K; Egle A; Melchardt T; Burgstaller S; Willenbacher E; Schalling M; Them NC; Kadlecova P; Klade C; Greil R
    Blood; 2015 Oct; 126(15):1762-9. PubMed ID: 26261238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C.
    Hsu SJ; Yu ML; Su CW; Peng CY; Chien RN; Lin HH; Lo GH; Su WW; Kuo HT; Hsu CW; Yang SS; Yang SS; Tseng KC; Qin A; Huang YW; Chuang WL
    J Formos Med Assoc; 2021 Mar; 120(3):956-964. PubMed ID: 33077341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera.
    Jin J; Zhang L; Qin A; Wu D; Shao Z; Bai J; Chen S; Duan M; Zhou H; Xu N; Zhang S; Zuo X; Du X; Wang L; Li P; Zhang X; Li Y; Zhang J; Wang W; Shen W; Zagrijtschuk O; Urbanski R; Sato T; Xiao Z
    Exp Hematol Oncol; 2023 Jun; 12(1):55. PubMed ID: 37344895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disappearance of a chromosomal abnormality in a young patient with polycythemia vera treated with ropeginterferon alfa-2b.
    Hosoda R; Hashimoto Y; Hara K; Maegaki M; Suzuki S; Hosoda Y; Kawamura K
    Ann Hematol; 2024 Sep; 103(9):3825-3827. PubMed ID: 39052033
    [No Abstract]   [Full Text] [Related]  

  • 18. [Interferon therapy for polycythemia vera].
    Edahiro Y
    Rinsho Ketsueki; 2023; 64(10):1290-1297. PubMed ID: 37914244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silent Thyroiditis Associated with Ropeginterferon α-2b in a Patient with Polycythemia Vera.
    Kirito K
    Intern Med; 2024 Mar; 63(6):843-846. PubMed ID: 37532547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in Polycythemia Vera Treatment: Ropeginterferon Alfa-2b in Light of Current Trials.
    Gisslinger H
    Turk J Haematol; 2023 Dec; 40(4):266-268. PubMed ID: 38050364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.